Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxametacin SCHEMBL29378857 | 0.90 | PTGS1 (1.00) | PTGS2PTGS1 | |
| SCHEMBL14405006 | 0.90 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Oxametacin SCHEMBL24552 | 0.90 | PTGS1 (1.00) | PTGS2PTGS1 | |
| SCHEMBL15709179 | 0.89 | PTGS2 (0.89) | PTGS2PTGS1 | |
| SCHEMBL9657228 | 0.89 | PTGS1 (0.85) | PTGS2PTGS1 | |
| SCHEMBL20259394 | 0.89 | PTGS2 (0.83) | PTGS2PTGS1 | |
| SCHEMBL11836498 | 0.89 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL11845952 | 0.89 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL11845946 | 0.89 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL23752275 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414067-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414067-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20060069256-A1 | Ophthalmic compositions for treating ocular hypertension | EVOTEC OAI (GB) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069256-A1 | Ophthalmic compositions for treating ocular hypertension | KCNN1, KCNN3, KCNN2 | PTGS2 122/4885PTGS1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.